Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643170 | 0.86 | CSF1R (0.36) | CSF1RMAP4K4EGFRERBB2DYRK1A | |
| SCHEMBL14361196 | 0.84 | SRC (0.39) | KCNH2CSF1RMAP4K4EGFRERBB2 | |
| SCHEMBL3278716 | 0.82 | SRC (0.39) | KCNH2CSF1RMAP4K4EGFRERBB2 | |
| SCHEMBL2819930 | 0.82 | CSF1R (0.40) | KCNH2CSF1RMAP4K4EGFRERBB2 | |
| SCHEMBL3272833 | 0.79 | CSF1R (0.38) | KCNH2MAP2K1CSF1RMAP4K4EGFR | |
| SCHEMBL24569776 | 0.77 | CSNK1A1 (0.38) | EGFRERBB2DYRK1ACLK4SRC | |
| SCHEMBL2770307 | 0.77 | KCNH2 (0.36) | KCNH2MAP4K4EGFR | |
| SCHEMBL2490082 | 0.77 | ERN1 (0.44) | KCNH2 | |
| SCHEMBL30083629 | 0.77 | CSNK1A1 (0.38) | EGFRERBB2DYRK1ACLK4SRC | |
| SCHEMBL29692876 | 0.77 | ERN1 (0.44) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| WO-2020098723-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | 上海轶诺药业有限公司 | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, ERBB2, ERBB3 | KCNH2 4266/4885MAP2K1 334/4885CSF1R 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.